Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S449000, C514S451000, C514S653000
Reexamination Certificate
active
07977377
ABSTRACT:
The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.
REFERENCES:
patent: 4560774 (1985-12-01), Pettit et al.
patent: 4833257 (1989-05-01), Pettit et al.
patent: 5072004 (1991-12-01), Pettit
patent: 5196447 (1993-03-01), Pettit et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5359115 (1994-10-01), Campbell et al.
patent: 5362899 (1994-11-01), Campbell
patent: 5393897 (1995-02-01), Pettit et al.
patent: 5625232 (1997-04-01), Numata et al.
patent: 5891870 (1999-04-01), Driedger et al.
patent: 5891906 (1999-04-01), Driedger et al.
patent: 5955501 (1999-09-01), Driedger et al.
patent: 5962498 (1999-10-01), Driedger et al.
patent: 5962504 (1999-10-01), Kozikowski et al.
patent: 6043270 (2000-03-01), Driedger et al.
patent: 6080784 (2000-06-01), Driedger et al.
patent: 6187568 (2001-02-01), Nishida et al.
patent: 2003/0171385 (2003-09-01), Alkon et al.
patent: 19943198 (2001-03-01), None
patent: WO 91/07087 (1991-05-01), None
patent: WO 92/10092 (1992-06-01), None
patent: WO 93/09668 (1993-05-01), None
patent: WO 93/20242 (1993-10-01), None
patent: WO 94/08051 (1994-04-01), None
patent: WO 98/32464 (1998-07-01), None
patent: 01/93883 (2001-12-01), None
patent: 02/083877 (2002-10-01), None
patent: 02/086106 (2002-10-01), None
patent: WO 02/087423 (2002-11-01), None
patent: WO 03/075930 (2003-09-01), None
patent: WO 2004/004641 (2004-01-01), None
patent: 2004/047857 (2004-06-01), None
Sun et al, “Depressed or Demented: Common CNS Drug Targets? !”, Current Drug Targets—CNS & Neurological Disorders, 2002, 1, 575-592.
European Search Report for EP 05 74 9738 dated Sep. 28, 2007.
F. Ferrari, “Behavioural Pharmacology of Imidazole, a Potential Antidepressant Agent”, Arch. int. Pharmacodyn, 277, 303-312 (1985).
A. Casini, et al., “Carbonic Anhydrase Activators. The Selective Serotonin Reuptake Inhibitors Fluoxetine, Sertaline and Citalopram are Strong Activators of Isozymes I and II”, Biooraanic & Medicinal Chemistry Letters 13 (2003) 2765-2768.
C. Supuran, et al., Carbonic Anhydrase Activators. XV. A Kinetic Study of Interaction of Bovine Isozyme II with Pyrazoles, Bis- and Tris-azolyl-methanes:, Biol. Pharm. Bull. 19(11) 1417-1422 (1996).
Partial European Search Report, Oct. 13, 2009.
Pettit, G.R., et al., “Antineoplastic agents 224 Isolation and Structure of Neristatin 1,” Journal of the American Chemical Society (1991), pp. 6693-6695, v.113(17).
Sun, et al. “Dual Effects of Bryostatin-1 on Spatial Memory and Depression,” European Journal of Pharmacology (2005), pp. 43-51, v. 512(1).
European Search Report dated Feb. 11, 2010.
Sun et al., “Carbonic anhydrase gating of attention: memory therapy and enhancement,” Trends in Pharmacological Sciences, vol. 23, No. 2, Feb. 2002.
Sun et al., “Functional switching of GABAergic synapses by ryanodine receptor activation,” Proc. Nat'l. Acad. Sci USA, 97: 12300-12305, 2000.
Battaini, “Protein Kinase C Isoforms as Therapeutic Targets in Nervous System Disease States,” Pharmacological Research, vol. 44, No. 5, 2001.
Coull et al., “Altered brain protein kinase C in depression: a post-mortem study,” European Neuropsychopharmacology 10 (2000) 283-288.
Manji et al., “Post-receptor Signaling Pathways in the Pathophysiology and Treatment of Mood Disorders,” Current Psychiatric Reports, 2000, 2:479-489.
Bouron et al., Acute Application of the Tricyclic Antidepressant Desipramine Presynaptically Stimulates the Exocytosis of Glutamate in the Hippocampus, Neuroscience, vol. 90, No. 3, pp. 729-736, 1999.
Budziszewska et al., “Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription—a possible mechanism,” British Journal of Phamacology, (2000) 130, 1385-1393.
Morishita et al., “Effects of tricylic antidepressants on protein kinase C activity in rabbit and human platelets in vivo,” Journal of Affective Disorders 70 (2002) 329-332.
Casini et al., “Carbonic Anhydrase Activators, The Selective Serotonin Reuptake Inhibitors Fluoxetine, Sertraline and Citalopram Are Strong Activators of Isozymes I and II,” Bioorganic & Medicinal Chemistry Letters 13 (2003) 2765-2768.
Wang et al., “Flouxetine Depresses Glutamate Exocytosis in the Rat Cerebrocortical Nerve Terminals (Synaptosomes) via Inhibition of P/Q Ca2+ Channels,” SYNAPSE 48:170-177 (2003).
Gould et al., “Signaling networks in the pathophysiology and treatment of mood disorders,” Journal of Psychosomatic Research 53 (2002) 687-697.
Abramets et al., “Behavioral Depression-Related Modifications of the Properties of Glutamatergic Synapses in the Basolateral Amygdalar Nucleus in Rats,” Neurophysiology, vol. 34, No. 4, 2002.
Shelton, “Cellular Mechanisms in the Vulnerability to Depression and Response to Antidepressants,” Psychiatric Clinics of North America, vol. 23, No. 4, Dec. 2000.
Popoli et al., “Second Messenger-Regulated Protein Kinases in the Brain: Their Functional Role and the Action of Antidepressant Drugs,” J. Neurochem., vol. 74, No. 1, 2000 21-31.
Johnston-Wilson et al., “Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder,” Molecular Psychiatry (2000) 5, 142-149.
Morishita et al., “Different effect of desipramine on protein kinase C in platelets between bipolar and major depressive disorders,” Psychiatry and Clinical Neurosciences (1999), 53, 11-15.
Lieb et al., “Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor,” Journal of Neurochemistry, 2003, 86, 69-76.
Suzuki et al., “Altered 5-HT-Induced Calcium Response in the Presence of Staurosporine in Blood Platelets from Bipolar Disorder Patients,” Neuropsychopharmacology (2003) 28, 1210-1214.
Hayes, “Acetozolamide in Bipolar Affective Disorders,” Annals of Clinical Psychiatry, vol. 6, No. 2, 1994.
Lenox et al., “Lithium and the Brain: A Psychopharmacological Strategy to a Molecular Basis for Manic Depressive Illness,” Clin. Chem. 40/2, 309-314 (1994).
Wang et al., “Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients,” Journal of Psychiatric Research 33 (1999) 171-179.
Manji et al., “Protein Kinace C Signaling in the Brain: Molecular Transduction of Mood Stabilization in the Treatment of Manic-Depressive Illness,” Biol Psychiatry 1999; 46:1328-1351.
Pandey et al., “Protein Kinase C and Phospholipase C Activity and Expression of Their Specific Isozymes is Decreased and Expression of MARCKS is Increased in Platelets of Bipolar but Not in Unipolar Patients,” Neuropschoparmacology, 2002, vol. 26, No. 2.
Yildiz, “Phosphoinositide metabolism, lithium and manic depresive illness,” Spectroscopy 16 (2002) 307-316.
Barbas et al., “Multiple Serotonergic Mechanisms Contributing to Sensitization in Aplysia: Evidence of Diverse Serotonin Receptor Subtypes,” Learning & Memory, 10: 373-386 (2003).
Pandey et al., “Protein Kinace C in Platelets of Depressed Patients,” Biol Psychiatry 1998; 44:909-911.
Besag, “Behavioral Effects of the New Anticonvulsants,” Drug Safety 2001: 24(7) 513-536.
Hahn et al., “Abnormalities in protein kinase C signaling and the pathphysiology of bipolar disorder,” Bipolar Disorders 1999: 2: 81-86.
International Search Report for PCT/US2005/017158 dated Dec. 14, 2006.
Mannisto, P.T. et al., “Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenyla
Alkon Daniel L.
Nelson Thomas J.
Sun Miao-Kun
Blanchette Rockefeller Neurosciences Institute
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Javanmard Sahar
Padmanabhan Sreeni
LandOfFree
Treatment of depressive disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of depressive disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of depressive disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696018